327 related articles for article (PubMed ID: 22706327)
41. Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study.
Hill KP; Palastro MD; Gruber SA; Fitzmaurice GM; Greenfield SF; Lukas SE; Weiss RD
Am J Addict; 2017 Dec; 26(8):795-801. PubMed ID: 28921814
[TBL] [Abstract][Full Text] [Related]
42. Vilazodone for cannabis dependence: A randomized, controlled pilot trial.
McRae-Clark AL; Baker NL; Gray KM; Killeen T; Hartwell KJ; Simonian SJ
Am J Addict; 2016 Jan; 25(1):69-75. PubMed ID: 26685701
[TBL] [Abstract][Full Text] [Related]
43. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study.
Ellegaard PK; Licht RW; Nielsen RE; Dean OM; Berk M; Poulsen HE; Mohebbi M; Nielsen CT
J Affect Disord; 2019 Feb; 245():1043-1051. PubMed ID: 30699846
[TBL] [Abstract][Full Text] [Related]
44. Who responds to a multi-component treatment for cannabis use disorder? Using multivariable and machine learning models to classify treatment responders and non-responders.
Tomko RL; Wolf BJ; McClure EA; Carpenter MJ; Magruder KM; Squeglia LM; Gray KM
Addiction; 2023 Oct; 118(10):1965-1974. PubMed ID: 37132085
[TBL] [Abstract][Full Text] [Related]
45. N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study.
Gray KM; Watson NL; Carpenter MJ; Larowe SD
Am J Addict; 2010; 19(2):187-9. PubMed ID: 20163391
[No Abstract] [Full Text] [Related]
46. N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study.
Prado E; Maes M; Piccoli LG; Baracat M; Barbosa DS; Franco O; Dodd S; Berk M; Vargas Nunes SO
Redox Rep; 2015 Sep; 20(5):215-22. PubMed ID: 25729878
[TBL] [Abstract][Full Text] [Related]
47. Psychosocial interventions for cannabis use disorder.
Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
[TBL] [Abstract][Full Text] [Related]
48. A placebo-controlled trial of buspirone for the treatment of marijuana dependence.
McRae-Clark AL; Carter RE; Killeen TK; Carpenter MJ; Wahlquist AE; Simpson SA; Brady KT
Drug Alcohol Depend; 2009 Nov; 105(1-2):132-8. PubMed ID: 19699593
[TBL] [Abstract][Full Text] [Related]
49. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study.
Suter PM; Domenighetti G; Schaller MD; Laverrière MC; Ritz R; Perret C
Chest; 1994 Jan; 105(1):190-4. PubMed ID: 8275731
[TBL] [Abstract][Full Text] [Related]
50. Potential role of N-acetylcysteine in the management of substance use disorders.
McClure EA; Gipson CD; Malcolm RJ; Kalivas PW; Gray KM
CNS Drugs; 2014 Feb; 28(2):95-106. PubMed ID: 24442756
[TBL] [Abstract][Full Text] [Related]
51. Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.
Baker NL; Gray KM; Sherman BJ; Morella K; Sahlem GL; Wagner AM; McRae-Clark AL
Drug Alcohol Depend; 2018 Jun; 187():270-277. PubMed ID: 29698894
[TBL] [Abstract][Full Text] [Related]
52. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
Cornelius JR; Bukstein OG; Douaihy AB; Clark DB; Chung TA; Daley DC; Wood DS; Brown SJ
Drug Alcohol Depend; 2010 Nov; 112(1-2):39-45. PubMed ID: 20576364
[TBL] [Abstract][Full Text] [Related]
53. N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial.
McKetin R; Dean OM; Turner A; Kelly PJ; Quinn B; Lubman DI; Dietze P; Carter G; Higgs P; Sinclair B; Reid D; Baker AL; Manning V; Pas NT; Thomas T; Bathish R; Raftery DK; Wrobel A; Saunders L; Arunogiri S; Cordaro F; Hill H; Hall S; Clare PJ; Mohebbi M; Berk M
EClinicalMedicine; 2021 Aug; 38():101005. PubMed ID: 34308314
[TBL] [Abstract][Full Text] [Related]
54. The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial.
Padoei F; Mamsharifi P; Hazegh P; Boroumand H; Ostadmohammady F; Abbaszadeh-Mashkani S; Banafshe HR; Matini AH; Ghaderi A; Dehkohneh SG
Brain Behav; 2023 Jan; 13(1):e2823. PubMed ID: 36448959
[TBL] [Abstract][Full Text] [Related]
55. Quetiapine treatment for cannabis use disorder.
Mariani JJ; Pavlicova M; Jean Choi C; Basaraba C; Carpenter KM; Mahony AL; Brooks DJ; Bisaga A; Naqvi N; Nunes EV; Levin FR
Drug Alcohol Depend; 2021 Jan; 218():108366. PubMed ID: 33153828
[TBL] [Abstract][Full Text] [Related]
56. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.
Marian AJ; Tan Y; Li L; Chang J; Syrris P; Hessabi M; Rahbar MH; Willerson JT; Cheong BY; Liu CY; Kleiman NS; Bluemke DA; Nagueh SF
Circ Res; 2018 Apr; 122(8):1109-1118. PubMed ID: 29540445
[TBL] [Abstract][Full Text] [Related]
57. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.
Hardan AY; Fung LK; Libove RA; Obukhanych TV; Nair S; Herzenberg LA; Frazier TW; Tirouvanziam R
Biol Psychiatry; 2012 Jun; 71(11):956-61. PubMed ID: 22342106
[TBL] [Abstract][Full Text] [Related]
58. N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial.
Arancini L; Bortolasci CC; Dodd S; Dean OM; Berk M
Trials; 2019 Sep; 20(1):555. PubMed ID: 31500670
[TBL] [Abstract][Full Text] [Related]
59. Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial.
Moist L; Sontrop JM; Gallo K; Mainra R; Cutler M; Freeman D; House AA
Am J Kidney Dis; 2010 Oct; 56(4):643-50. PubMed ID: 20541301
[TBL] [Abstract][Full Text] [Related]
60. N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
Grant JE; Chamberlain SR; Redden SA; Leppink EW; Odlaug BL; Kim SW
JAMA Psychiatry; 2016 May; 73(5):490-6. PubMed ID: 27007062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
